title: Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac.
abstract: OBJECTIVE
  Nano-diamino-tetrac (NDAT) targets a receptor on integrin αvβ3; αvβ3 is generously expressed by cancer cells and dividing endothelial cells and to a small extent by nonmalignant cells. The tetrac (tetraiodothyroacetic acid) of NDAT is covalently bound to a poly(lactic-co-glycolic acid) nanoparticle that encapsulates anticancer drugs. We report NDAT delivery efficiency of cisplatin to agent-susceptible urinary bladder cancer xenografts.
  
  
  METHODS
  Cisplatin-loaded NDAT (NDAT-cisplatin) was administered to xenograft-bearing nude mice. Tumor size response and drug content were measured.
  
  
  RESULTS
  Intratumoral drug concentration was up to fivefold higher (p < 0.001) in NDAT-cisplatin-exposed lesions than with conventional systemic administration. Tumor volume reduction achieved was NDAT-cisplatin > NDAT without cisplatin > cisplatin alone.
  
  
  CONCLUSIONS
  NDAT markedly enhances cisplatin delivery to urinary bladder cancer xenografts and increases drug efficacy.
authors.affiliation: Pharmaceutical Research Institute, Albany College of Pharmacy & Health Sciences, Rensselaer, NY 12144, USA.
authors.forename: Thangirala
authors.initials: T
authors.lastname: Sudha
authors.affiliation: Pharmaceutical Research Institute, Albany College of Pharmacy & Health Sciences, Rensselaer, NY 12144, USA.
authors.forename: Dhruba J
authors.initials: DJ
authors.lastname: Bharali
authors.affiliation: Pharmaceutical Research Institute, Albany College of Pharmacy & Health Sciences, Rensselaer, NY 12144, USA.|Department of Physiology, Faculty of Veterinary Medicine, Uludag University, Gorukle, 16059 Bursa, Turkey.
authors.forename: Murat
authors.initials: M
authors.lastname: Yalcin
authors.affiliation: Pharmaceutical Research Institute, Albany College of Pharmacy & Health Sciences, Rensselaer, NY 12144, USA.|Clinical Pathology Department, Hematology Unit, Faculty of Medicine, Mansoura University, Dakahliya 35516, Egypt.
authors.forename: Noureldien He
authors.initials: NH
authors.lastname: Darwish
authors.affiliation: Pharmaceutical Research Institute, Albany College of Pharmacy & Health Sciences, Rensselaer, NY 12144, USA.|Department of Biology, Faculty of Arts & Sciences, Uludag University, Gorukle, 16059 Bursa, Turkey.
authors.forename: Melis Debreli
authors.initials: MD
authors.lastname: Coskun
authors.affiliation: Pharmaceutical Research Institute, Albany College of Pharmacy & Health Sciences, Rensselaer, NY 12144, USA.
authors.forename: Kelly A
authors.initials: KA
authors.lastname: Keating
authors.affiliation: PhD Program for Cancer Biology and Drug Discovery, College of Medical Science & Technology, Taipei Medical University, Taipei 11031, Taiwan.|Taipei Cancer Center, Taipei Medical University, Taipei 11031, Taiwan.
authors.forename: Hung-Yun
authors.initials: HY
authors.lastname: Lin
authors.affiliation: Pharmaceutical Research Institute, Albany College of Pharmacy & Health Sciences, Rensselaer, NY 12144, USA.|Department of Medicine, Albany Medical College, Albany, NY, 12208, USA.
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Davis
authors.affiliation: Pharmaceutical Research Institute, Albany College of Pharmacy & Health Sciences, Rensselaer, NY 12144, USA.
authors.forename: Shaker A
authors.initials: SA
authors.lastname: Mousa
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology; D018929:Cell Culture Techniques; D045744:Cell Line, Tumor; D002470:Cell Survival; D002945:Cisplatin / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology; D016503:Drug Delivery Systems; D065546:Drug Liberation; D005260:Female; D064593:Heterografts; D006801:Humans; D039302:Integrin alphaVbeta3 / Q000378:metabolism; D019344:Lactic Acid / Q000737:chemistry*; D008819:Mice, Nude; D053758:Nanoparticles / Q000737:chemistry*; D009368:Neoplasm Transplantation; D009687:Nuclear Proteins / Q000737:chemistry / Q000378:metabolism; D010316:Particle Size; D011098:Polyglactin 910; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D013499:Surface Properties; D013974:Thyroxine / Q000031:analogs & derivatives; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy
chemical_list: C000626767:ASCC2 protein, human; D000970:Antineoplastic Agents; D039302:Integrin alphaVbeta3; D009687:Nuclear Proteins; C000626766:nano-diamino-tetrac; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D011098:Polyglactin 910; D002945:Cisplatin; D013974:Thyroxine
keywords: NDAT; cisplatin; integrin; nanotetrac; tetraiodothyroacetic acid; urinary bladder carcinoma